Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:

- Collaboration revenue (79.8%);

- Grant revenue (20.2%).

At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and three in phase I.

Number of employees : 830 people.
Sales per Business
20182019Delta
USD (in Million)%USD (in Million)%
Transformative Medicines135.07100%60.21100% -55.42%
Sales per region
20182019Delta
USD (in Million)%USD (in Million)%
United States135.07100%60.21100% -55.42%
Managers
NameAgeSinceTitle
Stéphane Bancel462011Chief Executive Officer & Director
Stephen Hoge432015President
Noubar Afeyan572012Chairman
David W. Meline612020Chief Financial Officer
Juan Andres542017Chief Technical Operations & Quality Officer
Tal Zaks, Dr.542015Chief Medical Officer
Paul Sagan602018Independent Non-Executive Director
Israel Ruiz472017Independent Non-Executive Director
Robert S. Langer, Dr.702010Independent Non-Executive Director
Stephen A. Berenson582017Independent Non-Executive Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 395,710,105 355,983,099 90.0% 0 0.0% 90.0%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 34,185,703 8.66%
Flagship Pioneering 32,973,227 8.36%
The Vanguard Group, Inc. 25,071,995 6.35%
Stéphane Bancel 23,658,428 6.00%
Robert S. Langer 11,509,357 2.92%
Thélème Partners LLP 7,652,978 1.94%
BlackRock Fund Advisors 7,253,490 1.84%
Baillie Gifford & Co. 7,225,636 1.83%
SSgA Funds Management, Inc. 6,583,927 1.67%
Geode Capital Management LLC 3,364,785 0.85%
Markets and indexes
-
- Nasdaq Global Select Market
- Nasdaq 100 /
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  MRNA.O
- Datastream Code :  
Company contact information
Moderna, Inc.
200 Square Technology
MA 02139 Cambridge, Massachusetts


Phone : +1 617 714 6500
Fax : +1 617 583 1998
web site : https://www.modernatx.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
MODERNA, INC.705.88%62 229
LONZA GROUP AG52.83%45 010
CELLTRION, INC.109.94%42 993
SEAGEN INC.57.68%32 484
IQVIA HOLDINGS INC.8.49%32 139
IMMUNOMEDICS, INC.315.22%20 324
INCYTE CORPORATION-5.78%18 155
HANGZHOU TIGERMED CONSULTING CO.,LTD105.86%16 319
ALNYLAM PHARMACEUTICALS, INC.13.89%15 239
PPD, INC.0.00%12 028
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.54.14%11 689
BIO-TECHNE CORPORATION36.19%11 542
PHARMARON BEIJING CO., LTD.95.44%11 490
QIAGEN N.V.41.54%10 897
ICON PUBLIC LIMITED COMPANY15.73%10 520
CRISPR THERAPEUTICS AG130.62%9 924
ACADIA PHARMACEUTICALS INC.24.54%8 470
GALAPAGOS NV-45.66%8 047
IONIS PHARMACEUTICALS, INC.-15.63%7 127
PRA HEALTH SCIENCES, INC.-0.33%7 106
NOVAVAX, INC.3,052.76%6 605